# US 2021/0340567 A1 · Cytokine immunotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0340567 A1
- Document ID: US20210340567A1
- Status: Published application
- Kind: A1
- Application number: 17/242,916
- Filed: 2021-04-28
- Published: 2021-11-04
- Earliest claimed: 2020-04-30
- Assignees: VLP Therapeutics, LLC
- Applicants: VLP Therapeutics, Inc.
- Inventors: Wataru AKAHATA; Jonathan F. SMITH
- Web page: https://patentgrep.com/patent/US20210340567A1

## CPC

- C12N 15/86: Viral vectors
- A61K 9/4825: {Proteins, e.g. gelatin (gelatin capsule shells with substantial amounts of other macromolecular substances A61K9/4816)}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 35/00: Antineoplastic agents
- C07K 14/5434: {IL-12}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2770/36143: viral genome or elements thereof as genetic vector
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided herein is a novel immunologically-active alphavirus replicon vector which comprises a nucleic acid encoding alphavirus nonstructural proteins nsp1-4 and a cytokine protein(s)/polypeptide(s), which is useful for the treatment of a cancer and/or an inflammatory disease.

## Claims

### Claim 1

An alphavirus replicon vector comprising, a polynucleotide which encodes alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4, and a polypeptide comprising a cytokine.

### Claim 2 (depends on 1)

The alphavirus replicon vector of claim 1, wherein the cytokine is a lymphokine, monokine, chemokine, or interleukin.

### Claim 3 (depends on 1)

The alphavirus replicon vector of claim 1, wherein the cytokine is an interleukin.

### Claim 4 (depends on 3)

The alphavirus replicon vector of claim 3, wherein the interleukin is interleukin-12 (IL-12).

### Claim 5 (depends on 1)

The alphavirus replicon vector of claim 1, wherein the cytokine is fused to a transmembrane domain.

### Claim 6 (depends on 5)

The alphavirus replicon vector of claim 5, wherein the transmembrane domain is derived from Influenza Hemagglutinin (HA) or TLR4.

### Claim 7 (depends on 5)

The alphavirus replicon vector of claim 5, wherein the transmembrane domain is fused to the cytokine by a linker.

### Claim 8 (depends on 7)

The alphavirus replicon vector of claim 7, wherein the linker is IgG4CH3.

### Claim 9 (depends on 1)

The alphavirus replicon vector of claim 1, which comprises a promoter, 5′ UTR, polynucleotide encoding alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4, SG promoter, a gene of interest encoding the polypeptide comprising a cytokine, 3′UTR and poly A tail.

### Claim 10 (depends on 1)

The alphavirus replicon vector claim 1, wherein the polypeptide comprising a cytokine has the amino acid sequence of SEQ ID NO: 14 or 18.

### Claim 11 (depends on 1)

The alphavirus replicon vector of claim 1, wherein the alphavirus is a CHIKV or VEEV.

### Claim 12 (depends on 11)

The alphavirus replicon vector of claim 11, wherein the alphavirus is selected from the group consisting of CHIKV strain 37997, CHIKV strain OPY-1 and VEEV strain TC-83.

### Claim 13 (depends on 1)

A composition comprising
(i) a pharmaceutically acceptable carrier, and
(ii) an alphavirus replicon vector of claim 1.

### Claim 14 (depends on 13)

The composition of claim 13, wherein the pharmaceutically acceptable carrier is a delivery vehicle and the alphavirus replicon vector is encapsulated in the delivery vehicle.

### Claim 15 (depends on 14)

The composition of claim 14, wherein the delivery vehicle is a particle consisting of alphavirus structural proteins or a lipid delivery system.

### Claim 16 (depends on 15)

The composition of claim 15, wherein the alphavirus structural proteins comprise a capsid and at least one envelope proteins and the capsid has one or more alterations in the Nuclear Localization Signal (NLS).

### Claim 17 (depends on 15)

The particle of claim 15, wherein the alphavirus structural proteins comprise at least one envelope protein E3 which comprises one or more alterations at the furin site in the E3 protein.

### Claim 18 (depends on 1)

The composition comprising a lipid nanoparticle and the alphavirus replicon vector of claim 1, wherein the alphavirus replicon vector is encapsulated in the lipid nanoparticle.

### Claim 19 (depends on 1)

A vaccine comprising the alphavirus replicon vector, particle or composition according to claim 1.

### Claim 20 (depends on 1)

A method of treating and/or immunizing against cancer or inflammatory disease in a subject, which comprises administering an effective amount of the alphavirus replicon vector of claim 1 to the subject in need thereof.
